Evidence map›Paper›PMID 34095343›Full record

ReviewMolecular therapy. Methods & clinical development2021

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing.

Eric Alves, Shahama Taifour, Riccardo Dolcetti, Jonathan Chee, Anna K Nowak, Silvana Gaudieri, Pilar Blancafort

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular therapy. Methods & clinical development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Eric AlvesSchool of Human Sciences, The University of Western Australia, Perth, WA 6009, Australia.
Shahama TaifourSchool of Human Sciences, The University of Western Australia, Perth, WA 6009, Australia.
Riccardo DolcettiDiamantina Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Jonathan CheeNational Centre for Asbestos Related Diseases, Institute of Respiratory Health, The University of Western Australia, Perth, WA 6009, Australia.
Anna K NowakNational Centre for Asbestos Related Diseases, Institute of Respiratory Health, The University of Western Australia, Perth, WA 6009, Australia.
Silvana GaudieriSchool of Human Sciences, The University of Western Australia, Perth, WA 6009, Australia.
Pilar BlancafortSchool of Human Sciences, The University of Western Australia, Perth, WA 6009, Australia.
The University of Western Australia · AUMurdoch University · AUThe University of Queensland · AUThe University of Texas Health Science Center at San Antonio · US

Funding

Targeted epigenetic silencing of oncogenic Transcription Factors (PQ18)R01CA170370 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLANCAFORT, PILAR · 2012 to 2015
$900k
Precision engineering of DNA methylation patterns in the human genomeR01DA036906 · NIDA · UNIVERSITY OF WESTERN AUSTRALIA · PI BLANCAFORT, PILAR, LISTER, RYAN · 2013 to 2014
$350k
NCI NIH HHS R01 CA170370NIDA NIH HHS R01 DA036906
6 · The paper itself

Abstract

Precise clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genetic and epigenetic manipulation of the immune response has become a promising immunotherapeutic approach toward combating tumorigenesis and tumor progression. CRISPR-based immunologic reprograming in cancer therapy comprises the locus-specific enhancement of host immunity, the improvement of tumor immunogenicity, and the suppression of tumor immunoevasion. To date, the

Indexed as

cancer immunotherapyclinical trialsCRISPRepigenome engineeringgenome editingimmune responseprecision medicine

Identifiers

PMID34095343
PMCPMC8142043
OpenAlexW3158331966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.